Mary-Kate Malecek

Mary-Kate Malecek, MD

Third-year Fellow

Began fellowship in 2018

Co-Chief Fellow (July 2019 - June 2021)


2010 BS in Chemical Engineering, University of Notre Dame, Notre Dame, IN
2014 MD, University of Illinois at Chicago College of Medicine, Chicago, IL
Post-graduate Training
2014-2017 Residency in Internal Medicine, McGaw Medical Center of Northwestern University, Chicago, IL
Work Experience
2017-2018 Instructor of Medicine, Division of Hospital Medicine, Washington University in St. Louis
Honors & Awards
2014 Gold Humanism Medical Honor Society, University of Illinois College of Medicine
2014 Alpha Omega Alpha Honor Medical Society, University of Illinois College of Medicine
2014-2017 Resident Teaching Award, Northwestern University Feinberg School of Medicine
2017 Arnold Widen Award for dedication to community service throughout residency, Northwestern University Feinberg School of Medicine


  • Intensive Induction Regimens After Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated With Improved Survival
    Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB
    Eur J Haematol 2021 May 11; [Epub ahead of print]
  • Prognosis and Risk Stratification of Peripheral T-Cell Lymphomas
    Malecek MK, Mehta-Shah N
    Semin Hematol 2021 Apr;58(2):70-77
  • Polatuzumab Vedotin for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Malecek MK, Watkins MP, Bartlett NL
    Expert Opin Biol Ther 2020 Jun 5; [Epub ahead of print]
  • Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment
    Malecek MK, Fiala M, Schroeder M, Dukeman J, Ghobadi A, Stockerl-Goldstein K, Wildes T, Vij R
    Clin Lymphoma Myeloma Leuk 2018 Sep;18(9):e363-e364
  • Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated With Dose-Adjusted EPOCH Plus Rituximab
    Malecek MK, Petrich AM, Rozell S, Chu B, Trifilio S, Galanina N, Maurer M, Farooq U, Link BK, Nowakowski GS, Nabhan C, Ayed AO
    Am J Hematol 2017 Nov;92(11):1156-1162
  • Advancements in Unresectable Melanoma: A Multidisciplinary Perspective
    Malecek MK, Robinson JK, Bilimoria K, Choi JN, Choi J, Gerami P, … Chandra S
    Melanoma Manag 2016;3(3):171-175
  • Repurposing Metformin for Cancer Treatment: Current Clinical Studies
    Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F
    Oncotarget 2016 Jun 28;7(26):40767-40780
  • Statins as Anti-Cancer Therapy; Can We Translate Preclinical and Epidemiologic Data Into Clinical Benefit?
    Chae YK, Yousaf M, Malecek MK, Carneiro B, Chandra S, Kaplan J, Kalyan A, Sassano A, Platanias LC, Giles F
    Discov Med 2015 Dec;20(112):413-27